US Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

US Bancorp DE increased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 323.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,795 shares of the company’s stock after acquiring an additional 24,286 shares during the quarter. US Bancorp DE’s holdings in Travere Therapeutics were worth $554,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. R Squared Ltd purchased a new position in Travere Therapeutics during the 4th quarter worth approximately $53,000. Quarry LP acquired a new stake in shares of Travere Therapeutics in the third quarter worth $105,000. Baader Bank Aktiengesellschaft purchased a new position in shares of Travere Therapeutics during the fourth quarter valued at $192,000. Aigen Investment Management LP acquired a new position in Travere Therapeutics during the third quarter valued at $170,000. Finally, Entropy Technologies LP acquired a new position in Travere Therapeutics during the fourth quarter valued at $214,000.

Insider Buying and Selling at Travere Therapeutics

In related news, insider Peter Heerma sold 1,584 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total transaction of $30,000.96. Following the completion of the transaction, the insider now owns 106,374 shares of the company’s stock, valued at approximately $2,014,723.56. The trade was a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total value of $258,300.00. Following the sale, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at approximately $945,842.94. The trade was a 21.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 206,335 shares of company stock worth $4,453,012 over the last 90 days. Insiders own 3.75% of the company’s stock.

Analyst Ratings Changes

TVTX has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Travere Therapeutics in a research note on Friday, February 21st. Citigroup raised their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, February 24th. Evercore ISI upped their price objective on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. lifted their target price on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Canaccord Genuity Group boosted their price target on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, Travere Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $30.62.

Travere Therapeutics Price Performance

NASDAQ TVTX opened at $18.13 on Wednesday. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $25.29. The stock’s 50-day moving average is $20.27 and its two-hundred day moving average is $17.62. The firm has a market cap of $1.61 billion, a P/E ratio of -4.42 and a beta of 0.75. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company had revenue of $74.79 million for the quarter, compared to analyst estimates of $72.38 million. On average, analysts anticipate that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.